<DOC>
	<DOCNO>NCT00085709</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine daunorubicin , work different way stop cancer cell divide stop grow die . Monoclonal antibody , gemtuzumab ozogamicin , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy gemtuzumab ozogamicin may kill cancer cell . It yet know whether induction therapy use cytarabine daunorubicin effective without gemtuzumab ozogamicin whether postconsolidation therapy use gemtuzumab ozogamicin effective additional therapy treat de novo ( first occurrence ) acute myeloid leukemia . PURPOSE : This randomized phase III trial compare two different regimen chemotherapy monoclonal antibody therapy see well work treat patient previously untreated de novo acute myeloid leukemia .</brief_summary>
	<brief_title>S0106 Cytarabine Daunorubicin w/ w/o Gemtuzumab Followed By HD Cytarabine Either Gemtuzumab Nothing de Novo AML</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient previously untreated de novo acute myeloid leukemia treat induction therapy comprise cytarabine daunorubicin v without gemtuzumab ozogamicin follow consolidation therapy comprise high-dose cytarabine post-consolidation therapy comprise gemtuzumab ozogamicin vs additional therapy . - Compare complete remission rate patient treat regimen . - Compare frequency severity toxic effect regimens patient . Other objective ( fund allows ) : - Determine prognostic significance CD33 expression response rate patient receive gemtuzumab ozogamicin . - Determine prognostic significance FLT3 mutation patient treatment regimen . - Determine prognostic significance minimal residual disease remission specimens patient treat regimen . - Determine prognostic significance flow cytometric detection minimal residual disease specimen collect patient treated regimen . OUTLINE : This randomize , multicenter study . Patients stratified induction therapy accord age ( &lt; 35 year vs ≥ 35 year ) post-consolidation therapy accord preinduction cytogenetic risk group . - Induction therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive daunorubicin IV day 1-3 , cytarabine IV continuously day 1-7 , gemtuzumab ozogamicin IV 2 hour day 4 . Patients receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) IV subcutaneously daily begin day 15 continue blood count recover . - Arm II : Patients receive daunorubicin , cytarabine , G-CSF GM-CSF arm I . Patients arm undergo bone marrow aspiration biopsy day 14 ( day 19 , applicable ) proceed reinduction therapy . - Reinduction therapy : Patients receive daunorubicin IV day 1-3 cytarabine IV continuously day 1-7 . Patients also receive G-CSF GM-CSF induction therapy . Patients achieve A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status proceed consolidation therapy . - Consolidation therapy : Patients receive high-dose cytarabine IV 3 hour twice daily day 1 , 3 , 5 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Patients maintain A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status consolidation therapy proceed post-consolidation therapy . - Post-consolidation therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Arm II : Patients receive additional therapy . Patients observe day 30 60 randomization . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 684 patient ( 342 per treatment arm ) accrue study within 4.5-5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) bone marrow aspiration biopsy* within past 14 day No M3 disease NOTE : *Patients mark leukocytosis may register availability biopsy result absolute blast count ≥ 100,000 cells/µL No blastic transformation chronic myelogenous leukemia No preexist hematologic disorder evolve AML ( e.g. , myelodysplasia secondary leukemia ) PATIENT CHARACTERISTICS : Age 18 60 Performance status Zubrod 03 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN No known hepatitis B C infection No know liver disease Renal Not specify Cardiovascular LVEF ≥ 50 % MUGA echocardiogram No unstable cardiac arrhythmia No unstable angina Other No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Prior hydroxyurea control high cell count allow No 1 prior dose intrathecal chemotherapy acute leukemia Concurrent intrathecal chemotherapy allow induction therapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>